Compare ELVR & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVR | MPLT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 903.2M | 811.3M |
| IPO Year | N/A | N/A |
| Metric | ELVR | MPLT |
|---|---|---|
| Price | $49.92 | $17.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 55.5K | ★ 155.3K |
| Earning Date | 04-28-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $90.03 | N/A |
| Revenue Next Year | $42.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.55 | $12.24 |
| 52 Week High | $69.99 | $21.55 |
| Indicator | ELVR | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 41.19 |
| Support Level | $49.59 | $16.17 |
| Resistance Level | $59.05 | $20.73 |
| Average True Range (ATR) | 2.92 | 1.32 |
| MACD | -0.56 | -0.21 |
| Stochastic Oscillator | 54.40 | 13.14 |
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.